Distinguished in Peripheral T-Cell Lymphoma

Daobin B. Zhou

Peking Union Medical College Hospital, Peking Union Medical College, 
Beijing, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Peripheral T-Cell Lymphoma
Peking Union Medical College Hospital, Peking Union Medical College, 
Beijing, CN 
OverviewLocationsClinical Research

Overview

Daobin Zhou practices in Beijing, China. Zhou is rated as a Distinguished expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. Their top areas of expertise are Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Bone Marrow Aspiration, and Splenectomy.

Their clinical research consists of co-authoring 334 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 17 articles in the study of Peripheral T-Cell Lymphoma.

Locations

Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Recruiting
Publish Date: January 23, 2024
Intervention Type: Drug
Study Drug: APG2575
Study Phase: Phase 2
A Phase II, Multicenter, Open, Single-arm Study of TQB2450 Injection (PD-L1 Antibody) in Subjects With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
A Phase II, Multicenter, Open, Single-arm Study of TQB2450 Injection (PD-L1 Antibody) in Subjects With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
Enrollment Status: Terminated
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

334 Total Publications

A case of osteopetrosis type Ⅱ presenting with anemia, splenomegaly, and thrombocytopenia
A case of osteopetrosis type Ⅱ presenting with anemia, splenomegaly, and thrombocytopenia
Journal: Zhonghua nei ke za zhi
Published: October 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhou's expertise for a condition
ConditionClose
    View All 18 Advanced Conditions
    View All 58 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile